HeartSciences Inc. HSCS

, an analyst from Maxim Group, reiterated the Buy rating on Heart Test Laboratories, Inc. ( – ). The associated price target is $12.00.
Allen Klee’s rating is based on a thorough analysis of Heart Test Laboratories, Inc.’s current position and future prospects. The company’s recent F1Q25 financial results were roughly in line with expectations, demonstrating that their research and development efforts, although leading to a slightly higher EBITDA loss than anticipated, are on track with the FDA submission process for their innovative MyoVista device and AI-ECG algorithm. Klee acknowledges the company’s proactive movements towards software-based solutions, international collaborations, and a strategic partnership with Mount Sinai, which bolster the company’s potential for growth and market penetration.

--
+0.00%
SEATTLE, Nov. 16, 2023 /PRNewswire/ -- 1606 Corp. (the "Company" or "1606") (OTC Pink: CBDW) has announced that it has established a pricing model and full presentation of deliverables for ChatCBDW in preparation for upcoming marketing campaigns.

Video Press Release
ChatCBDW available to test at CBDW.AI
This presentation is for informational and educational use only and is not a recommendation

CBDW it’s hot watch the video
It’s merging with amazon

https://www.youtube.com/watch?v=JEJTZ-7HIXM

https://www.youtube.com/watch?v=JEJTZ-7HIXM

INSIDER NAME INSIDER POSITION FILING DATE BUY/SELL STOCK/OPTION SHARES SHARES CHANGE PRICE COST FINAL SHARE
Bruce Bent Director 19/03/2023 ET Buy Option 50K 0% $0.00 $0.00 50K
Danielle Watson 19/03/2023 ET Buy Option 75K 0% $0.00 $0.00 75K
Brian Szymczak Director 19/03/2023 ET Buy Option 50K 0% $0.00 $0.00 50K
Andrew Simpson Director 19/03/2023 ET Buy Option 300K 0% $0.00 $0.00 300K
David Wells Director 19/03/2023 ET Buy Option 50K 0% $0.00 $0.00 50K
MARK HILZ Director 19/03/2023 ET Buy Option 300K 0% $0.00 $0.00 300K
Medical Device Pipeline
DEVICE
STAGE
DECISION DATE
MyoVista
Heart disease
Pre-submission

Patient enrollment completed May 9, 2023. DeNovo resubmission planned.
Latest HSCS Press Releases

$0.21
-0.01 -5.09%
PREVIOUS CLOSE
0.23
OPEN
0.24
52 WEEK LOW
0.14
52 WEEK HIGH
3.95
MARKET CAP
$2.34M
OPTIONS
N
SHARES
10.92M
FLOAT
9.63M
ENTERPRISE VALUE
$3.59M
VOLUME
16.23M
AV. DAILY VOLUME
6.56M

20/11/2023 08:00AM ET
HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
Southlake, TX, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the closing of its license agreements with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai), in New York, NY, to develop and commercialize electrocardiographic AI algorithms and assets. The licenses result in Icahn Mount Sinai becoming a shareholder in the Company.

Andrew Simpson, Chief Executive Officer of HeartSciences, said, "We continue to advance initiatives that fundamentally transform and de-risk HeartSciences. The closing of our licenses with Icahn Mount Sinai now propels us forward with our cardiovascular disease AI-ECG development programs. Combined with the recent creation of a new FDA product classification for AI-ECG algorithms that we believe paves the way for a more structured and quicker 510(k) process of our technologies, we have clear focus on our target milestones," said Andrew Simpson, CEO of HeartSciences. "We believe AI-based ECG algorithms close the diagnostic gap to detect heart disease much earlier and at a lower cost and we look forward to accelerating commercialization and broadening the range of prospective solutions that we will provide."

$HSCS looks like its over for today… but maybe $ZOM or $ATNX next?

?